Lymphoma

NEW ORLEANS — Chimeric antigen receptor T cells demonstrated acceptable efficacy with no additional safety concerns when administered to patients with non-Hodgkin lymphoma and HIV, retrospective study results showed.

NEW ORLEANS — The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma, according to study results.

NEW ORLEANS — Odronextamab showed promising efficacy among patients with grade 1 to grade 3a follicular lymphoma who received two or more prior lines of therapy, according to study results presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — Patients with newly diagnosed mantle cell lymphoma who received ibrutinib with a standard-of-care regimen had higher failure-free survival rates than those who received standard-of-care treatment alone.

Up to one-quarter of those seeking clinical trial enrollment for novel front-line therapies to treat diffuse large B-cell lymphoma are excluded based on organ function laboratory values, study results showed.

The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

The treatment landscape of lymphoma has expanded rapidly within the last year, including recent FDA approvals and new designations of drugs in the pipeline.

Treatment regimens for diffuse large B-cell lymphoma have seen many recent advancements, thanks in large part to the development of targeted agents.

The FDA granted priority review to epcoritamab for treatment of certain patients with advanced lymphoma, according to the agent’s manufacturer.

Women who underwent implant reconstruction after mastectomy for breast cancer or ductal carcinoma in situ had a significantly increased relative risk for anaplastic large cell lymphoma, according to findings published in JAMA Network Open.